|
⚲
|
| Keyboard |
| Kemps-Polanco Reshema
✚
|
|
|---|---|
| CIK # | 0002009357 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 3 | [0002009357] | |
| 4 | [0002009357] |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| Charles River Laboratories International Inc | |
| Kemps-Polanco Reshema |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Charles River Laboratories International Inc CRL
Stock Options (Right to Buy) · derivative
|
2025-05-21 | Grant | 2,076 | $134.98 | 280,218 |
|
Charles River Laboratories International Inc CRL
Common Stock
|
2025-05-21 | Grant | 946 | $134.98 | 127,691 |
|
Charles River Laboratories International Inc CRL
Common Stock
|
2025-05-21 | Grant | 630 | $134.98 | 85,037 |
|
Charles River Laboratories International Inc CRL
Stock Options (Right to Buy) · derivative
|
2024-05-13 | Grant | 1,311 | $228.41 | 299,446 |
|
Charles River Laboratories International Inc CRL
Common Stock
|
2024-05-13 | Grant | 285 | $228.41 | 65,097 |
|
Charles River Laboratories International Inc CRL
Common Stock
|
2024-05-13 | Grant | 559 | $228.41 | 127,681 |
|
Charles River Laboratories International Inc CRL
Common Stock
|
2024-02-01 | Grant | 170 | $0.00 | |
|
Charles River Laboratories International Inc CRL
Stock Options (Right to Buy) · derivative
|
2024-02-01 | Grant | 399 | $219.54 | 87,596 |